Zimmer Biomet Stock Falls As Weakness In Latin America And Certain EU Markets Impact Organic Growth Forecast

1. ZBH's Q3 adjusted earnings rose 9.2% year over year, surpassing estimates. 2. Sales reached $2.001 billion, slightly below consensus but showing 7% growth. 3. Knee and hip products saw solid growth, but international markets struggled. 4. Adjusted operating margin stood at 26.5%, reflecting strong cost management. 5. Guidance for FY 2025 remains steady, despite lowered organic growth outlook.